Completed PHASE3 INTERVENTIONAL 2-arm NCT00641719

A Long-term Study for the Treatment of Painful Diabetic Neuropathy

A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase

Sponsor: Eli Lilly and Company

Conditions Diabetic Neuropathies

Interventions Duloxetine hydrochloride

Updated 8 times since 2017 Last updated: Mar 3, 2011 Started: Mar 31, 2008 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetic Neuropathies, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Shionogi

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Aomori, Japan , Chiba, Japan , Fukui, Japan , Fukuoka, Japan , Fukushima, Japan , Gunma, Japan , Hiroshima, Japan , Hokkaido, Japan , Hyōgo, Japan and 15 more locations